Testing the Effects of Methylphenidate on Multiple Sclerosis
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue,
characterized by a lack of energy, feelings of exhaustion, an the perception that one is
unable to partake in daily activities. The goal of this project is to test whether
methylphenidate (MP), a well-known psychostimulant, can effective treat fatigue experienced
by individuals with MS.
The current study will test the effect of MP on MS fatigue through a clinical trial. Every
participant in the study will be exposed to both the drug and the placebo for a period of
time. Both the investigators and participants will be unaware whether participants are
receiving the drug or the placebo.
Upon successful completion of the study, physicians will be able to evaluate the potential
prescription of MP to treat fatigue in persons with MS based on solid research evidence.
Importantly, MP is already an FDA approved widely used medication in multiple clinical
populations.